Findings

What do systematic reviews say?

238 questions · 242 findings · 21 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 37 · 15.3%GRADE not reported 15 · 6.2%Very low 78 · 32.2%Low 52 · 21.5%Moderate 49 · 20.2%High 11 · 4.5%

Atypical antipsychotics vs placebo (only short term)

Weight gain (equal or greater then 7% of baseline) · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 106 participants
High

Atypical antipsychotics vs placebo (only short term)

High prolactin at any time during treatment · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
High

Atypical antipsychotics vs placebo (only short term)

Change in corrected QT · people with psychosis

1 finding from 1 review

Atypical antipsychotics for psychosis in adolescents 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
High

Atypical antipsychotics vs placebo

Irritability · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…

1 finding from 1 review

Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) 2023 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 973 participants
Moderate

Atypical antipsychotics vs placebo

Aggression · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…

1 finding from 1 review

Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 77 participants
Very low

Atypical antipsychotics vs placebo

Self‐injury · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…

1 finding from 1 review

Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Low

Atypical antipsychotics vs placebo

Adverse effects (AEs) · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…

Atypical antipsychotics may leads to higher adverse effects (AEs) compared with placebo (low certainty).

1 finding from 1 review

Pharmacological intervention for irritability, aggression, and self‐injury in autism spectrum disorder (ASD) 2023 · Cochrane Headline outcomes only
RR 4.19
11 studies · 974 participants
Low

Atypical antipsychotics vs placebo

Gambling symptom severity · treatment of disordered and problem gambling

1 finding from 1 review

Pharmacological interventions for the treatment of disordered and problem gambling 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 63 participants
Very low

Atypical antipsychotics vs placebo

Gambling expenditure · treatment of disordered and problem gambling

1 finding from 1 review

Pharmacological interventions for the treatment of disordered and problem gambling 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

Atypical antipsychotics vs placebo

Gambling frequency ‐ not measured · treatment of disordered and problem gambling

1 finding from 1 review

Pharmacological interventions for the treatment of disordered and problem gambling 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

Atypical antipsychotics vs placebo

Time spent gambling ‐ not measured · treatment of disordered and problem gambling

1 finding from 1 review

Pharmacological interventions for the treatment of disordered and problem gambling 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

Atypical antipsychotics vs placebo

Depressive symptoms · treatment of disordered and problem gambling

1 finding from 1 review

Pharmacological interventions for the treatment of disordered and problem gambling 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

Atypical antipsychotics vs placebo

Anxiety · treatment of disordered and problem gambling

1 finding from 1 review

Pharmacological interventions for the treatment of disordered and problem gambling 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

Atypical antipsychotics vs placebo

Functional impairment ‐ not measured · treatment of disordered and problem gambling

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for the treatment of disordered and problem gambling 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Atypical antipsychotics vs placebo

Responder status · treatment of disordered and problem gambling

Atypical antipsychotics showed no clear difference in responder status compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for the treatment of disordered and problem gambling 2022 · Cochrane Headline outcomes only
RR 0.93 [0.62, 1.4]
1 study · 42 participants
Low

Atypical antipsychotics vs placebo

Psychosis ‐ presented in units of NPI‐NH P (higher is worse)d ‐ 3364 persons in 12 RCTs of 3 to 12 weeks

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atypical antipsychotics vs placebo

Response for psychosis ‐ as defined by authors of RCTs ‐ 1958 persons in 7 RCTs of 3 to 12 weeks

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Atypical antipsychotics vs placebo

Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Atypical antipsychotics vs placebo

Somnolence

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
High

Atypical antipsychotics vs placebo

Death ‐ 5032 persons in 17 RCTs of 3 to 12 weeks ___________________________________________

1 finding from 1 review

Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate